In this issue of the Journal, Verdonck et al.1 report on a studythat, as they planned it, was barely large enough to detecta massive advantage for a controversial and expensive therapy.Moreover, the way they calculated the size of their sample wastoo forgiving: it presupposed a one-sided test of significance,which ordinarily would not be acceptable in these pages. Yetthe study does appear here, and it provides evidence strongenough to guide therapeutic decisions. What went right?
Verdonck et al. studied patients with non-Hodgkin's lymphomawho had partial responses to three cycles of CHOP therapy (cyclophosphamide,. . . [Full Text of this Article]
References
Related Letters:
Bone Marrow Transplantation versus Chemotherapy in Non-Hodgkin's Lymphoma
Seymour J. F., Flecknoe-Brown S., Mross K., Burke H. B., Nimer S. D., Zelenetz A., Portlock C., Finckh W., Fielding A. K., Pearce R. M., Goldstone A. H., Selwyn M. R., Verdonck L. F., van Putten W. L.J., Hagenbeek A., Walker A. M.
Extract |
Full Text
N Engl J Med 1995;
333:727-730, Sep 14, 1995.
Correspondence
This article has been cited by other articles:
Andreotti, F., Pasceri, V., Hackett, D. R., Davies, G. J., Haider, A. W., Maseri, A.
(1996). Preinfarction Angina as a Predictor of More Rapid Coronary Thrombolysis in Patients with Acute Myocardial Infarction. NEJM
334: 7-12
[Abstract][Full Text]
Seymour, J. F., Flecknoe-Brown, S., Mross, K., Burke, H. B., Nimer, S. D., Zelenetz, A., Portlock, C., Finckh, W., Fielding, A. K., Pearce, R. M., Goldstone, A. H., Selwyn, M. R., Verdonck, L. F., van Putten, W. L.J., Hagenbeek, A., Walker, A. M.
(1995). Bone Marrow Transplantation versus Chemotherapy in Non-Hodgkin's Lymphoma. NEJM
333: 727-730
[Full Text]